Skip to main content

Advertisement

SpringerLink
Log in

Gonadal hormone substitutes

  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Darwin C. The origin of species. London, 1859.

  2. Purdie DW, Steel SA, Howey S, Doherty SM. Technical and logistical feasibility of population densitometry using DXA and directed HRT intervention: a two year prospective study. Osteoporosis int 1996;6(Suppl 3):S31–5.

    Google Scholar 

  3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of oestrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med 1995;332:1589.

    Google Scholar 

  4. Yang N, Venugopalan M, Hardikar S, Glasebrook A. Identification of an oestrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996;273:1222–4.

    Google Scholar 

  5. Turner RT, Wakley GK, Hannan KS, Bell NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987:2:449–56.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Metabolic Bone Disease, University of Hull, Hull, UK

    D. W. Purdie

Authors
  1. D. W. Purdie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Purdie, D.W. Gonadal hormone substitutes. Osteoporosis Int 7 (Suppl 1), 61–63 (1997). https://doi.org/10.1007/BF01674816

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01674816

Keywords

Search

Navigation